+

RU2016122867A3 - - Google Patents

Download PDF

Info

Publication number
RU2016122867A3
RU2016122867A3 RU2016122867A RU2016122867A RU2016122867A3 RU 2016122867 A3 RU2016122867 A3 RU 2016122867A3 RU 2016122867 A RU2016122867 A RU 2016122867A RU 2016122867 A RU2016122867 A RU 2016122867A RU 2016122867 A3 RU2016122867 A3 RU 2016122867A3
Authority
RU
Russia
Application number
RU2016122867A
Other languages
Russian (ru)
Other versions
RU2669805C2 (en
RU2016122867A (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2016122867A publication Critical patent/RU2016122867A/en
Publication of RU2016122867A3 publication Critical patent/RU2016122867A3/ru
Application granted granted Critical
Publication of RU2669805C2 publication Critical patent/RU2669805C2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
RU2016122867A 2013-12-25 2014-12-22 (6s,9as)-n-benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazin-1-yl)azethydin-1-yl]pyridine-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1h-pyrasino[2,1-c][1,2,4]triazine-1-carboxamide compound RU2669805C2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013-267687 2013-12-25
JP2013267687 2013-12-25
PCT/JP2014/083932 WO2015098853A1 (en) 2013-12-25 2014-12-22 (6S,9aS)-N-BENZYL-6-[(4-HYDROXYPHENYL)METHYL]-4,7-DIOXO-8-({6-[3-(PIPERAZINE-1-YL)AZETIDINE-1-YL]PYRIDINE-2-YL}METHYL)-2-(PROP-2-EN-1-YL)-OCTAHYDRO-1H-PYRAZINO[2,1-c][1,2,4]TRIAZINE-1-CARBOXAMIDE COMPOUND

Publications (3)

Publication Number Publication Date
RU2016122867A RU2016122867A (en) 2018-02-01
RU2016122867A3 true RU2016122867A3 (en) 2018-06-18
RU2669805C2 RU2669805C2 (en) 2018-10-16

Family

ID=53399298

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016122867A RU2669805C2 (en) 2013-12-25 2014-12-22 (6s,9as)-n-benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazin-1-yl)azethydin-1-yl]pyridine-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1h-pyrasino[2,1-c][1,2,4]triazine-1-carboxamide compound

Country Status (35)

Country Link
US (1) US9174998B2 (en)
EP (1) EP3088401B1 (en)
JP (1) JP6085040B2 (en)
KR (1) KR102307053B1 (en)
CN (1) CN105873932B (en)
AR (1) AR098908A1 (en)
AU (1) AU2014371148B2 (en)
BR (1) BR112016013572B1 (en)
CA (1) CA2932435C (en)
CL (1) CL2016001419A1 (en)
CY (1) CY1122521T1 (en)
DK (1) DK3088401T3 (en)
ES (1) ES2728353T3 (en)
HK (1) HK1222656A1 (en)
HR (1) HRP20190908T1 (en)
HU (1) HUE044541T2 (en)
IL (1) IL245961A0 (en)
JO (1) JO3809B1 (en)
LT (1) LT3088401T (en)
ME (1) ME03391B (en)
MX (1) MX365376B (en)
MY (1) MY173946A (en)
PE (1) PE20160932A1 (en)
PH (1) PH12016501079A1 (en)
PL (1) PL3088401T3 (en)
PT (1) PT3088401T (en)
RS (1) RS58955B1 (en)
RU (1) RU2669805C2 (en)
SG (1) SG11201604496YA (en)
SI (1) SI3088401T1 (en)
SM (1) SMT201900306T1 (en)
TR (1) TR201908392T4 (en)
TW (1) TWI681961B (en)
UA (1) UA116923C2 (en)
WO (1) WO2015098853A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
WO2016031841A1 (en) 2014-08-28 2016-03-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 High-purity quinoline derivative and method for manufacturing same
CN107427505A (en) 2015-02-25 2017-12-01 卫材R&D管理有限公司 Method for suppressing the bitter taste of quinoline derivatives
KR20250020678A (en) 2015-03-04 2025-02-11 머크 샤프 앤드 돔 엘엘씨 Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
US11369623B2 (en) * 2015-06-16 2022-06-28 Prism Pharma Co., Ltd. Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
MX2017015257A (en) * 2015-06-23 2018-02-19 Eisai R&D Man Co Ltd CRYSTAL OF (6S,9aS)-N-BENZYL-6-[(4-HYDROXYPHENYL)METHYL]- 4,7-DIOXO-8-({6-[3-(PIPERAZIN-1-YL)AZETIDIN-1-YL]PYRIDIN- 2-YL}METHYL)-2-(PROP-2-EN-1-YL)-OCTAHYDRO-1H-PYRAZINO[2,1-c][1, 2,4]TRIAZINE-1-CARBOXAMIDE COMPOUND.
EP3338779B1 (en) 2015-08-20 2021-06-30 Eisai R&D Management Co., Ltd. Lenvatinib in combination with etoposide and ifosfamide for use in treating a tumor
CN108084067B (en) * 2016-11-22 2019-08-30 重庆圣华曦药业股份有限公司 A kind of preparation method of Li Tasite intermediate
EP3581183B1 (en) * 2017-02-08 2023-11-29 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
CA3061888A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
US20220409724A1 (en) 2019-10-29 2022-12-29 Eisai R&D Management Co., Ltd. Combination of a pd-1 antagonist, a vegfr/fgfr/ret tyrosine kinase inhibitor and a cbp/beta-catenin inhibitor for treating cancer
CN115835865A (en) 2020-03-12 2023-03-21 3+2 制药有限责任公司 CBP/catenin signaling pathway inhibitors and uses thereof
WO2022092294A1 (en) 2020-10-30 2022-05-05 学校法人慶應義塾 Novel treatment and prevention of sarcopenia-related diseases
US20240352020A1 (en) * 2021-08-26 2024-10-24 3+2 Pharma, Llc Pyrazole-containing cbp/catenin antagonists and uses thereof
EP4364742A1 (en) 2021-09-08 2024-05-08 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating solid tumors
CN116262120A (en) * 2021-12-13 2023-06-16 上海中医药大学 Application of reagents specifically binding to TRAF2 in preparation of Wnt pathway inhibitors
WO2023140369A1 (en) * 2022-01-18 2023-07-27 Prism BioLab Co., Ltd. Phosphoric acid derivatives
JPWO2023190748A1 (en) 2022-03-31 2023-10-05
CN115784934A (en) * 2022-11-22 2023-03-14 上海吉奉生物科技有限公司 Synthetic method of tyrosine derivative

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2310215T3 (en) * 2001-10-12 2009-01-01 Choongwae Pharma Corporation MIMETIC STRUCTURES OF REVERSE TURN AND RELATED METHOD.
US7671054B1 (en) * 2001-10-12 2010-03-02 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US8080657B2 (en) * 2001-10-12 2011-12-20 Choongwae Pharma Corporation Compounds of reverse turn mimetics and the use thereof
JP2009184924A (en) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd Compound for biological reagent
WO2009148192A1 (en) * 2008-06-06 2009-12-10 Prism Biolab Corporation Alpha helix mimetics and methods relating thereto
MX340424B (en) * 2009-04-15 2016-07-08 Jw Pharmaceutical Corp Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof.
JP5809279B2 (en) 2010-10-14 2015-11-10 ジェイダブリュ ファーマセウティカル コーポレーション Novel compounds of reverse turn analogues and their production and use
US20140051706A1 (en) * 2011-02-25 2014-02-20 Prism Pharma Co., Ltd. Alpha helix mimetics and methods relating thereto

Also Published As

Publication number Publication date
EP3088401B1 (en) 2019-03-06
RS58955B1 (en) 2019-08-30
UA116923C2 (en) 2018-05-25
DK3088401T3 (en) 2019-06-03
SI3088401T1 (en) 2019-08-30
BR112016013572B1 (en) 2023-03-21
PE20160932A1 (en) 2016-09-10
CN105873932B (en) 2017-11-24
JP6085040B2 (en) 2017-02-22
NZ720718A (en) 2020-10-30
TW201609736A (en) 2016-03-16
KR102307053B1 (en) 2021-10-01
US9174998B2 (en) 2015-11-03
AU2014371148A1 (en) 2016-06-23
WO2015098853A1 (en) 2015-07-02
PT3088401T (en) 2019-06-12
LT3088401T (en) 2019-07-25
CY1122521T1 (en) 2021-01-27
MX365376B (en) 2019-05-31
AU2014371148B2 (en) 2018-08-09
ES2728353T3 (en) 2019-10-23
MY173946A (en) 2020-02-28
BR112016013572A2 (en) 2017-10-03
PL3088401T3 (en) 2019-09-30
HRP20190908T1 (en) 2019-08-09
SG11201604496YA (en) 2016-07-28
RU2669805C2 (en) 2018-10-16
JPWO2015098853A1 (en) 2017-03-23
IL245961A0 (en) 2016-08-02
KR20160094980A (en) 2016-08-10
RU2016122867A (en) 2018-02-01
CA2932435A1 (en) 2015-07-02
AR098908A1 (en) 2016-06-22
TWI681961B (en) 2020-01-11
MX2016007705A (en) 2017-01-11
ME03391B (en) 2020-01-20
CA2932435C (en) 2021-08-17
CL2016001419A1 (en) 2017-01-20
HK1222656A1 (en) 2017-07-07
PH12016501079A1 (en) 2016-07-11
SMT201900306T1 (en) 2019-07-11
TR201908392T4 (en) 2019-07-22
HUE044541T2 (en) 2019-10-28
EP3088401A1 (en) 2016-11-02
US20150175615A1 (en) 2015-06-25
JO3809B1 (en) 2021-01-31
CN105873932A (en) 2016-08-17
EP3088401A4 (en) 2017-06-28

Similar Documents

Publication Publication Date Title
AP2016009275A0 (en)
BR112016011606A2 (en)
BR112015007533A2 (en)
BR112014018502A2 (en)
BR112014019326A2 (en)
BR112014018516A2 (en)
BR112014017855A2 (en)
BR112014018480A2 (en)
BR112014020341A2 (en)
BR112015017863A2 (en)
BR112014021878A2 (en)
RU2016122867A3 (en)
BR112016010873A2 (en)
BR112014018468A2 (en)
BR112014017901A2 (en)
BR112014018207A2 (en)
BR112014019204A2 (en)
BR112015015948A2 (en)
BR112016003540A2 (en)
BR112014018578A2 (en)
BR112014018483A2 (en)
BR112014017794A2 (en)
BR112014018496A2 (en)
BR112015015312A2 (en)
BR112014018353A2 (en)
点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载